# CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Source: https://onco.cc/trials/nct03328078/  
OnCo record `nct03328078` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ibrutinib in brain and spinal cord tumours, run by Curis, Inc., now recruiting.

## Summary

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) is a phase 1/2 interventional study registered as NCT03328078 by Curis, Inc., with 152 participants planned, started 2017-12-28 and due to reach its primary completion in 2026-08. Interventions recorded: Emavusertib and Ibrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03328078
- Phase: 1/2
- Setting: An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
- Sponsor: Curis, Inc.
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT03328078: https://clinicaltrials.gov/study/NCT03328078

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Emavusertib](https://onco.cc/drugs/emavusertib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/)
- companies: [Curis](https://onco.cc/companies/curis/)

---
JSON: https://onco.cc/api/v1/entities/nct03328078.json